Acute myeloid leukemia
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Ziftomenib + Induction Chemotherapy (7+3) | Blood cancer, Acute myeloid leukemia, Cancer | Phase 3 | Dec 31, 2028 | Mgmt interest |
| Ziftomenib + venetoclax + azacitidine | Blood cancer, Acute myeloid leukemia, Cancer | Phase 3 | Dec 31, 2028 | Mgmt interest |
| Ziftomenib + venetoclax/azacitidine | Acute myeloid leukemia | Phase 1b | Dec 31, 2026 | — |
Upcoming milestones
Company profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Acute myeloid leukemia
Data readoutBlood cancer, Acute myeloid leukemia, Cancer
Data readout